2,2-Dimethylbutanoic acid
2,2-Dimethylbutanoic acid structure
|
Common Name | 2,2-Dimethylbutanoic acid | ||
|---|---|---|---|---|
| CAS Number | 595-37-9 | Molecular Weight | 116.16 | |
| Density | 0.9±0.1 g/cm3 | Boiling Point | 187.3±8.0 °C at 760 mmHg | |
| Molecular Formula | C6H12O2 | Melting Point | -14°C | |
| MSDS | Chinese USA | Flash Point | 79.4±0.0 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 862(1-2) , 168-74, (2008) 2,2-Dimethylbutyrate (DMB) is a potential treatment for thalassemia and hemoglobinopathies. To facilitate pharmacokinetic evaluation of DMB, we developed an LC-MS assay and quantitated DMB in plasma of rats after an oral dose of 500mg/kg. After acetonitrile p... |
|
|
[Chemical components of essential oils from the herb of Ligularia virgaurea].
Zhongguo Zhong Yao Za Zhi 28(7) , 627-9, (2003) To provide the foundation for reasonable utilization by analyzing the essential oils of Ligularia virgaurea.The essential oils were extracted by using steam distillation and separated with GC capillary columns. The components were quantitatively determined wi... |
|
|
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.
Br. J. Haematol. 161(4) , 587-93, (2013) β-thalassaemia intermedia (BTI) syndromes cause haemolytic anaemia, ineffective erythropoiesis, and widespread complications. Higher fetal globin expression within genotypes reduces globin imbalance and ameliorates anaemia. Sodium 2,2 dimethylbutyrate (HQK-10... |
|
|
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
Am. J. Hematol. 87(11) , 1017-21, (2012) Therapeutics which reduce the pathology in sickle cell syndromes are needed, particularly noncytotoxic therapeutics. Fetal hemoglobin (HbF, α(2) γ(2) ) is established as a major regulator of disease severity; increased HbF levels correlate with milder clinica... |
|
|
Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.
J. Clin. Pharmacol. 51(8) , 1186-94, (2011) Pharmacologic induction of fetal globin synthesis is an accepted therapeutic strategy for treatment of the beta hemoglobinopathies and thalassemias, as even small increases in hemoglobin F (HbF) levels reduce clinical severity in sickle cell disease (SCD) and... |
|
|
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Am. J. Hematol. 88(11) , E255-60, (2013) 2,2-Dimethylbutyrate (HQK-1001), an orally-bioavailable promoter-targeted fetal globin gene-inducing agent, was evaluated in an open-label, randomized dose-escalation study in 52 subjects with hemoglobin SS or S/β(0) thalassemia. HQK-1001 was administered dai... |
|
|
Short-term toxicity study of ST-20 (NSC-741804) by oral gavage in Sprague-Dawley rats.
Toxicol. Pathol. 39(4) , 614-22, (2011) ST-20 (sodium 2,2-dimethylbutyrate) is a potential therapeutic agent for treatment of β-thalassemia and sickle cell disease. A subchronic oral toxicity study was conducted in Sprague-Dawley rats (10/sex/dose) at gavage dosages of 0 (vehicle control), 200, 600... |
|
|
Metabolic fate of 2,2-dimethylbutyryl moiety of simvastatin in rats: identification of metabolites by gas chromatography/mass spectrometry.
Eur. J. Drug Metab. Pharmacokinet. 16(3) , 189-96, (1991) Metabolic pathways of simvastatin (MK-733), a lactone prodrug of an inhibitor of HMG-CoA reductase, were elucidated in male rats, using the [14C]-labelled compound. Evidence has been obtained for hydrolysis of simvastatin and its metabolites at their 2,2-dime... |